Journal of Clinical Immunology

, Volume 30, Issue 6, pp 886–893 | Cite as

Diffuse Large B Cell Lymphoma in Hyper-IgE Syndrome Due To STAT3 Mutation

  • Attila Kumánovics
  • Sherrie L. Perkins
  • Heather Gilbert
  • Melissa H. Cessna
  • Nancy H. Augustine
  • Harry R. Hill


The Job or hyper-immunoglobulinemia E syndrome is a primary immunodeficiency that is usually inherited in an autosomal dominant fashion. With the discovery of mutations in the STAT3 gene in the majority of autosomal dominant cases, it is now possible to make a molecular diagnosis of hyper-IgE syndrome. Both primary and secondary immunodeficiencies, including hyper-IgE syndrome, may predispose for malignancies, especially lymphomas, mainly mature B cell lymphomas, and classical Hodgkin lymphoma. Here, we report of a 48-year-old male with hyper-IgE syndrome who developed a primary parotid gland diffuse large B cell lymphoma. Analysis for STAT3 mutations demonstrated that the causal mutation of hyper-IgE syndrome, R382Q, arose de novo in the patient and it was transmitted to three of his five children, all three of whom are clinically affected. We review the literature regarding lymphoma in hyper-IgE syndrome and the possible etiologic relationship with STAT3 mutations.


Immunodeficiency hyper-IgE syndrome Job syndrome lymphoma STAT3 melting analysis 


Disclosure/conflict of interest

The authors have no conflicts of interests to declare.


  1. 1.
    Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N Engl J Med. 1999;340:692–702.CrossRefPubMedGoogle Scholar
  2. 2.
    Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev. 2005;203:244–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125:424–32. e428.CrossRefPubMedGoogle Scholar
  4. 4.
    Davis SD, Schaller J, Wedgwood RJ. Job's syndrome. Recurrent, “cold”, staphylococcal abscesses. Lancet. 1966;1:1013–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608–19.CrossRefPubMedGoogle Scholar
  6. 6.
    Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Jiao H, Toth B, Erdos M, Fransson I, Rakoczi E, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46:202–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Minegishi Y, Karasuyama H. Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency. Curr Opin Allergy Clin Immunol. 2007;7:506–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kumánovics A, Wittwer CT, Pryor RJ, Augustine NH, Leppert MF, Carey JC, et al. Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases. J Mol Diagn. 2010;12:213–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Al Khatib S, Keles S, Garcia-Lloret M, Karakoc-Aydiner E, Reisli I, Artac H, et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol. 2009;124:342–8. e341–345.CrossRefPubMedGoogle Scholar
  14. 14.
    Renner ED, Puck JM, Holland SM, Schmitt M, Weiss M, Frosch M, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr. 2004;144:93–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124:1289–302. e1284.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361:2046–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Woellner C, Schaffer AA, Puck JM, Renner ED, Knebel C, Holland SM, et al. The hyper IgE syndrome and mutations in TYK2. Immunity. 2007;26:535. author reply 536.CrossRefPubMedGoogle Scholar
  19. 19.
    Belada D, Smolej L, Stepankova P, Kralickova P, Freiberger T. Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: successful treatment with risk-adapted rituximab-based immunochemotherapy. Leuk Res. 2010;34:e232–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Chang CH, Hsu YH. Hyper-IgE syndrome with Epstein–Barr virus associated extranodal NK/T cell lymphoma of skin. Kaohsiung J Med Sci. 2010;26:206–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Bale Jr JF, Wilson JF, Hill HR. Fatal histiocytic lymphoma of the brain associated with hyperimmunoglobulinemia-E and recurrent infections. Cancer. 1977;39:2386–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Nester TA, Wagnon AH, Reilly WF, Spitzer G, Kjeldsberg CR, Hill HR. Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Med. 1998;105:162–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM, et al. Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review. Leuk Lymphoma. 2004;45:2521–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Clark TJ, Herod JJ, Kehoe S, Luesley DM. The development of invasive vulvar cancer in a patient with Job's syndrome, a rare immunodeficient condition. Br J Obstet Gynaecol. 1998;105:468–70.PubMedGoogle Scholar
  25. 25.
    Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka M, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 1997;94:13897–902.CrossRefPubMedGoogle Scholar
  26. 26.
    Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009;324:1713–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323:793–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001;98:762–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168:466–74.PubMedGoogle Scholar
  30. 30.
    Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004;6:439–44.CrossRefPubMedGoogle Scholar
  31. 31.
    Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11:623–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008;111:1515–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303.CrossRefPubMedGoogle Scholar
  36. 36.
    Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–15.CrossRefPubMedGoogle Scholar
  37. 37.
    Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.CrossRefPubMedGoogle Scholar
  38. 38.
    Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004;114:720–8.PubMedGoogle Scholar
  40. 40.
    Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA. 1997;94:6764–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006;108:1058–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Onal IK, Kurt M, Altundag K, Aksoy S, Dincer M, Gullu I. Peripheral T-cell lymphoma and Job's syndrome: a rare association. Med Oncol. 2006;23:141–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Ruusala A, Aspenstrom P. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett. 2004;572:159–66.CrossRefPubMedGoogle Scholar
  44. 44.
    Randall KL, Lambe T, Johnson AL, Treanor B, Kucharska E, Domaschenz H, et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol. 2009;10:1283–91.CrossRefPubMedGoogle Scholar
  45. 45.
    Lei JY, Wang Y, Jaffe ES, Turner ML, Raffeld M, Sorbara L, et al. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am J Dermatopathol. 2000;22:524–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Idbaih A, Carvalho Silva R, Criniere E, Marie Y, Carpentier C, Boisselier B, et al. Genomic changes in progression of low-grade gliomas. J Neurooncol. 2008;90:133–40.CrossRefPubMedGoogle Scholar
  47. 47.
    Kang JU, Koo SH, Kwon KC, Park JW. Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. Int J Oncol. 2010;37:327–35.PubMedGoogle Scholar
  48. 48.
    Takahashi K, Kohno T, Ajima R, Sasaki H, Minna JD, Fujiwara T, et al. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Int J Oncol. 2006;28:321–8.PubMedGoogle Scholar
  49. 49.
    Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, et al. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 2003;112:673–84.CrossRefPubMedGoogle Scholar
  50. 50.
    Gorin LJ, Jeha SC, Sullivan MP, Rosenblatt HM, Shearer WT. Burkitt's lymphoma developing in a 7-year-old boy with hyper-IgE syndrome. J Allergy Clin Immunol. 1989;83:5–10.CrossRefPubMedGoogle Scholar
  51. 51.
    Einsele H, Saal JG, Dopfer R, Niethammer D, Waller HD, Muller CA. Highly malignant non-Hodgkin's lymphoma in hyper-IgE syndrome. Dtsch Med Wochenschr. 1990;115:1141–4.CrossRefPubMedGoogle Scholar
  52. 52.
    Kowalchuk RM. Case of the season. Job's syndrome with superimposed lymphoma. Semin Roentgenol. 1996;31:254–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Lin SJ, Huang JL, Hsieh KH. Hodgkin's disease in a child with hyperimmunoglobulin E syndrome. Pediatr Hematol Oncol. 1998;15:451–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Huber KK, Cole KJ, Greene JN, Sandin RL, Vincent AL, Brown R. Malignancies associated with hyper-IgE syndrome: case and review. Infect Dis Clin Practice. 2000;9:128–30.CrossRefGoogle Scholar
  55. 55.
    Mosseri R, Finkelstein Y, Monselize Y, Garty BZ. Large T-cell lymphoma in a 13-year-old girl with hyperimmunoglobulinemia E syndrome. Pediatr Allergy Immunol. 2002;13:143–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. Extensive xanthelasma associated with anaplastic large cell lymphoma and hyperimmunoglobulin E syndrome. Int J Dermatol. 2003;42:944–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Kashef MA, Kashef S, Handjani F, Karimi M. Hodgkin lymphoma developing in a 4.5-year-old girl with hyper-IgE syndrome. Pediatr Hematol Oncol. 2006;23:59–63.CrossRefPubMedGoogle Scholar
  58. 58.
    Wallet N, Ghez D, Delarue R, Suarez F, Rubio MT, Fischer A, et al. Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome. Clin Lymphoma Myeloma. 2007;7:425–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Attila Kumánovics
    • 1
  • Sherrie L. Perkins
    • 1
    • 5
  • Heather Gilbert
    • 2
  • Melissa H. Cessna
    • 3
  • Nancy H. Augustine
    • 1
    • 5
  • Harry R. Hill
    • 1
    • 2
    • 4
    • 5
  1. 1.Department of PathologyUniversity of Utah School of MedicineSalt Lake CityUSA
  2. 2.Department of MedicineUniversity of Utah School of MedicineSalt Lake CityUSA
  3. 3.LDS Hospital and Intermountain Central LaboratorySalt Lake CityUSA
  4. 4.Department of PediatricsUniversity of Utah School of MedicineSalt Lake CityUSA
  5. 5.ARUP Institute for Clinical and Experimental PathologySalt Lake CityUSA

Personalised recommendations